share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  06/05 17:17
Moomoo AI 已提取核心訊息
On June 3, 2024, Mangoceuticals, Inc., a company listed on the Nasdaq Capital Market under the trading symbol MGRX, reported significant corporate activities through a Form 8-K filing with the SEC. The company issued 192,308 shares of restricted common stock to a third-party consultant for professional relations and consulting services, with an agreement lasting until May 23, 2025. The consultant will also receive $15,000 monthly and additional stock compensation after six and nine months of service. These transactions are exempt from registration under the Securities Act due to the private nature of the offering and the accredited status of the recipient. Furthermore, Mangoceuticals granted 1,250,000 fully-vested shares to certain officers, an employee, and directors as part of their 2022 Equity Plan. CEO and Chairman Jacob D. Cohen received the largest share allocation with 800,000 shares. The equity awards are a bonus for services rendered in 2024. The company's actions reflect its ongoing compensation strategy and commitment to its executive team and board members.
On June 3, 2024, Mangoceuticals, Inc., a company listed on the Nasdaq Capital Market under the trading symbol MGRX, reported significant corporate activities through a Form 8-K filing with the SEC. The company issued 192,308 shares of restricted common stock to a third-party consultant for professional relations and consulting services, with an agreement lasting until May 23, 2025. The consultant will also receive $15,000 monthly and additional stock compensation after six and nine months of service. These transactions are exempt from registration under the Securities Act due to the private nature of the offering and the accredited status of the recipient. Furthermore, Mangoceuticals granted 1,250,000 fully-vested shares to certain officers, an employee, and directors as part of their 2022 Equity Plan. CEO and Chairman Jacob D. Cohen received the largest share allocation with 800,000 shares. The equity awards are a bonus for services rendered in 2024. The company's actions reflect its ongoing compensation strategy and commitment to its executive team and board members.
2024年6月3日,一家掛牌於納斯達克資本市場,交易代碼為MGRX的公司Mangoceuticals通過向SEC提交的8-K文件報告了重大企業活動。該公司向第三方顧問發行了192308股限制性普通股,用於專業關係和諮詢服務,協議期至2025年5月23日。該顧問還將獲得每月1.5萬美元的報酬,並在提供服務後六個月和九個月後獲得額外的股票報酬。由於此交易是私募,且收件人是認可的投資者,因此這些交易免除了根據證券法的註冊要求。此外,Mangoceuticals將125萬股完全彌補的股票授予某些高級職員、一名員工和董事,作為2022年股權計劃的一部分。首席執行官和主席Jacob D. Cohen獲得了最大的股份分配,為80萬股。這些股票獎勵是對其在2024年提供服務的獎勵。該公司的行動反映出其不斷的補償策略,以及對其執行團隊和董事會成員的承諾。
2024年6月3日,一家掛牌於納斯達克資本市場,交易代碼為MGRX的公司Mangoceuticals通過向SEC提交的8-K文件報告了重大企業活動。該公司向第三方顧問發行了192308股限制性普通股,用於專業關係和諮詢服務,協議期至2025年5月23日。該顧問還將獲得每月1.5萬美元的報酬,並在提供服務後六個月和九個月後獲得額外的股票報酬。由於此交易是私募,且收件人是認可的投資者,因此這些交易免除了根據證券法的註冊要求。此外,Mangoceuticals將125萬股完全彌補的股票授予某些高級職員、一名員工和董事,作為2022年股權計劃的一部分。首席執行官和主席Jacob D. Cohen獲得了最大的股份分配,為80萬股。這些股票獎勵是對其在2024年提供服務的獎勵。該公司的行動反映出其不斷的補償策略,以及對其執行團隊和董事會成員的承諾。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息